A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial

Bradbury, Andrew W; Moakes, Catherine A; Popplewell, Matthew; Meecham, Lewis; Bate, Gareth R; Kelly, Lisa; Chetter, Ian; Diamantopoulos, Athanasios; Ganeshan, Arul; Hall, Jack; Hobbs, Simon; Houlind, Kim; Jarrett, Hugh; Lockyer, Suzanne; Malmstedt, Jonas; Patel, Jai V; Patel, Smitaa; Rashid, S Tawqeer; Saratzis, Athanasios; Slinn, Gemma; Scott, D Julian A; Zayed, Hany; Deeks, Jonathan J

Abstract

Background
Chronic limb-threatening ischaemia is the severest manifestation of peripheral arterial disease and presents with ischaemic pain at rest or tissue loss (ulceration, gangrene, or both), or both. We compared the effectiveness of a vein bypass first with a best endovascular treatment first revascularisation strategy in terms of preventing major amputation and death in patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion.

Methods
Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL)-2 was an open-label, pragmatic, multicentre, phase 3, randomised trial done at 41 vascular surgery units in the UK (n=39), Sweden (n=1), and Denmark (n=1). Eligible patients were those who presented to hospital-based vascular surgery units with chronic limb-threatening ischaemia due to atherosclerotic disease and who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion. Participants were randomly assigned (1:1) to receive either vein bypass (vein bypass group) or best endovascular treatment (best endovascular treatment group) as their first revascularisation procedure through a secure online randomisation system. Participants were excluded if they had ischaemic pain or tissue loss considered not to be primarily due to atherosclerotic peripheral artery disease. Most vein bypasses used the great saphenous vein and originated from the common or superficial femoral arteries. Most endovascular interventions comprised plain balloon angioplasty with selective use of plain or drug eluting stents. Participants were followed up for a minimum of 2 years. Data were collected locally at participating centres. In England, Wales, and Sweden, centralised databases were used to collect information on amputations and deaths. Data were analysed centrally at the Birmingham Clinical Trials Unit. The primary outcome was amputation-free survival defined as time to first major (above the ankle) amputation or death from any cause measured in the intention-to-treat population. Safety was assessed by monitoring serious adverse events up to 30-days after first revascularisation. The trial is registered with the ISRCTN registry, ISRCTN27728689.

Findings
Between July 22, 2014, and Nov 30, 2020, 345 participants (65 [19%] women and 280 [81%] men; median age 72·5 years [62·7–79·3]) with chronic limb-threatening ischaemia were enrolled in the trial and randomly assigned: 172 (50%) to the vein bypass group and 173 (50%) to the best endovascular treatment group. Major amputation or death occurred in 108 (63%) of 172 patients in the vein bypass group and 92 (53%) of 173 patients in the best endovascular treatment group (adjusted hazard ratio [HR] 1·35 [95% CI 1·02–1·80]; p=0·037). 91 (53%) of 172 patients in the vein bypass group and 77 (45%) of 173 patients in the best endovascular treatment group died (adjusted HR 1·37 [95% CI 1·00–1·87]). In both groups the most common causes of morbidity and death, including that occurring within 30 days of their first revascularisation, were cardiovascular (61 deaths in the vein bypass group and 49 in the best endovascular treatment group) and respiratory events (25 deaths in the vein bypass group and 23 in the best endovascular treatment group; number of cardiovascular and respiratory deaths were not mutually exclusive).

Interpretation
In the BASIL-2 trial, a best endovascular treatment first revascularisation strategy was associated with a better amputation-free survival, which was largely driven by fewer deaths in the best endovascular treatment group. These data suggest that more patients with chronic limb-threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal, revascularisation procedure to restore limb perfusion should be considered for a best endovascular treatment first revascularisation strategy.

Citation

Bradbury, A. W., Moakes, C. A., Popplewell, M., Meecham, L., Bate, G. R., Kelly, L., Chetter, I., Diamantopoulos, A., Ganeshan, A., Hall, J., Hobbs, S., Houlind, K., Jarrett, H., Lockyer, S., Malmstedt, J., Patel, J. V., Patel, S., Rashid, S. T., Saratzis, A., Slinn, G., …Deeks, J. J. (2023). A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet, 401(10390), 1798-1809. https://doi.org/10.1016/s0140-6736%2823%2900462-2

• Journal Article Type: Article
• Acceptance Date: Jan 15, 2023
• Online Publication Date: Apr 25, 2023
• Publication Date: 2023-05
• Deposit Date: May 23, 2025
• Publicly Available Date: Jun 11, 2025
• Journal: The Lancet
• Print ISSN: 0140-6736
• Electronic ISSN: 1474-547X
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 401
• Issue: 10390
• Pages: 1798-1809
• DOI: https://doi.org/10.1016/s0140-6736%2823%2900462-2
• Keywords: SLI, severe limb ischaemia, vein bypass, endovascular
• Public URL: https://nottingham-repository.worktribe.com/output/49283057
• Publisher URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00462-2/fulltext
• Additional Information: This article is maintained by: Elsevier; Article Title: A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial; Journal Title: The Lancet; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(23)00462-2; CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(23)00632-3; Content Type: article; Copyright: © 2023 The Author(s). Published by Elsevier Ltd.